Article Sidebar

Download
PDF
Statistic
Read Counter : 915 Download : 1737

Downloads

Download data is not yet available.

Main Article Content

Abstract

[LAFIAL: COVID-19 Pandemic As The Pharmaceutical Industry's Independence Momentum Towards National Health Resilience] Ninety percent of the distribution of medicinal raw materials and medical devices of the domestic pharmaceutical industry is sourced from imports from other countries. One of the exporter countries is China which still feels it has sovereignty over part of the North Natuna Sea (LNU) in the South China Sea conflict (LCS). In the conflict, Indonesia vehemently denies any unilateral claims from China. This has the potential to stop import access to Indonesia which ultimately has an impact on the development of the domestic pharmaceutical industry. In Presidential Instruction No. 6 of 2016, the government wants the realization of the resilience of the domestic pharmaceutical industry. Industrial resilience in the pharmaceutical sector has multi-benefits including accelerating national economic growth, meeting the scarcity of pharmaceutical products and medical devices as a result of COVID-19, and at the same time reducing import dependence on medicinal raw materials and medical devices. Navy Pharmaceutical Institute (LAFIAL) as the military pharmaceutical industry has a strategic capacity and role against both military and nonmilitary threats that can harm the health of the people of Indonesia. The involvement of LAFIAL is expected to further encourage and strengthen the independence of the pharmaceutical industry. This article is qualitative research through a descriptive approach with an analysis of studies from several references to describe the current pharmaceutical industry profile and the COVID-19 pandemic impact affecting the pharmaceutical industry independence, coupled with interviews from several sources. The interview results provide an overview of how the  LAFIAL benefits as a military pharmaceutical industry to support health defense, especially during the COVID-19 pandemic.

Article Details

License

The journal allows the author(s) to hold the copyright without restrictions.


Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

How to Cite
Ruskar, D., Hastuti, S., Wahyudi, H., Dewa Ketut Kerta Widana, I., & Khoirudin Apriyadi, R. (2021). LAFIAL: Pandemi COVID-19 Sebagai Momentum Kemandirian Industri Farmasi Menuju Ketahanan Kesehatan Nasional. PENDIPA Journal of Science Education, 5(3), 300–308. https://doi.org/10.33369/pendipa.5.3.300-308
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Admin KNIC. (2020). Perkembangan Industri Farmasi di Indonesia Dari Zaman Penjajahan Hingga di Tengah Pandemi. Retrieved from https://www.knic.co.id/id/bagaimana-perkembangan-industri-farmasi-di-indonesia
  2. Agustina, S., & Herman, S. (2016). Potensi mikroalga sebagai bahan kimia ADI. Bbkk. Kemenperin. Go. Id, 3(1).
  3. Agustino, L. (2020). Analisis Kebijakan Penanganan Wabah Covid-19: Pengalaman Indonesia. Jurnal Borneo Administrator, 16(2), 253–270. Retrieved from https://doi.org/10.24258/jba.v16i2.685
  4. Alam, S. O. (2020). Masuk 5 Besar, Kasus COVID-19 Indonesia Peringkat Berapa di Asia? Retrieved from https://health.detik.com/berita-detikhealth/d-5277872/masuk-5-besar-kasus-covid-19-indonesia-peringkat-berapa-di-asia
  5. Ariawan, I., & Jusril, H. (2020). COVID-19 in Indonesia: Where Are We? Acta Medica Indonesiana, 52(3), 193.
  6. Arman. (2019). Lembaga Farmasi Angkatan Laut Dipercaya Sebagai Industri Farmasi Dalam Mengembangkan OST-D. Retrieved from https://www.liputanindonesianews.com/detail/28492/lembaga-farmasi-angkatan-laut-dipercaya-sebagai-industri-farmasi-dalam-mengembangkan-ostd.html
  7. Herdady, M. R., & Muchtaridi, M. (2020). COVID-19: Alarm Bagi Sistem Rantai Pasok Industri Farmasi. Majalah Farmasetika. Retrieved from https://doi.org/10.24198/mfarmasetika.v5i4.27076
  8. Indramadhini, L., & Sitompul, P. P. (2015). PENGARUH KAUSALITAS EKSPOR, IMPOR, DAN GDP DI INDONESIA. Media Ekonomi, 23(1), 11. Retrieved from https://doi.org/10.25105/me.v23i1.3292
  9. Junus, D. (2016). PENGEMBANGAN KAPASITAS DINAS KESEHATAN KABUPATEN GORONTALO. Jurnal Ad’ministrare, 3(1), 51–56. Retrieved from https://doi.org/10.26858/ja.v3i1.1927
  10. Kaban, R., Siregar, R. S. M., Sumarlin, S., Yusrina, P., Yunita, R., & Aritonang, R. P. (2018). Perancangan Web Responsive Untuk Sistem Informasi Obat-Obatan. Jurnal Manajemen Bisnis (JMB), 30(2).
  11. Kemenperin. (2020). Kemenperin Pertajam Taji Industri Farmasi dan Alat Kesehatan.
  12. Lardo, S. (2020). STRATEGI PEMBANGUNAN KESEHATAN DAN KETAHANAN NASIONAL DALAM PERSPEKTIF DAYA JUANG BANGSA. Jurnal Pertahanan & Bela Negara, 10(1), 61. Retrieved from https://doi.org/10.33172/jpbh.v10i1.824
  13. Lee, Y. H., & Kim, Y. (2016). Analyzing interaction in R&D networks using the Triple Helix method: Evidence from industrial R&D programs in Korean government. Technological Forecasting and Social Change, 110, 93–105. Retrieved from https://doi.org/https://doi.org/10.1016/j.techfore.2015.10.017
  14. Mahfut, M. (2020). APLIKASI FILOGENETIK DI DUNIA BIOLOGI KESEHATAN: MELACAK PANDEMI PATOGEN. TEKNOSAINS: MEDIA INFORMASI SAINS DAN TEKNOLOGI, 14(2). Retrieved from https://doi.org/10.24252/teknosains.v14i2.15406
  15. Mawarti, R. S. (2017). PROSPEK INDUSTRI FARMASI DI INDONESIA. Jurnal Inspirasi, 8(2), 69–72. Retrieved from https://doi.org/10.35880/inspirasi.v8i2.105
  16. Moerti, W. (2021). Data Terkini Covid-19 di Indonesia Januari 2021. Retrieved from https://www.merdeka.com/peristiwa/data-terkini-covid-19-di-indonesia-januari-2021.html
  17. Ngurah Diksa, I. G. B. (2021). Peramalan Gelombang Covid 19 Menggunakan Hybrid Nonlinear Regression Logistic – Double Exponential Smoothing di Indonesia dan Prancis. Jambura Journal of Mathematics, 3(1), 37–51. Retrieved from https://doi.org/10.34312/jjom.v3i1.7771
  18. Nugroho, A. W. (2017). REVIEW: KONSERVASI KEANEKARAGAMAN HAYATI MELALUI TANAMAN OBAT DALAM HUTAN DI INDONESIA DENGAN TEKNOLOGI FARMASI: POTENSI DAN TANTANGAN. Jurnal Sains Dan Kesehatan, 1(7), 377–383. Retrieved from https://doi.org/10.25026/jsk.v1i7.71
  19. Puskes TNI. (2020). Penerimaan Vitarma Tablet produk Lafial untuk penanganan Covid-19. Retrieved from http://puskes-tni.mil.id/detail-berita.php?idberita=42
  20. Raharni, R., Supardi, S., & Sari, I. D. (2018). Kemandirian dan Ketersediaan Obat Era Jaminan Kesehatan Nasional (JKN): Kebijakan, Harga, dan Produksi Obat. Media Penelitian Dan Pengembangan Kesehatan, 28(4), 219–228. Retrieved from https://doi.org/10.22435/mpk.v28i4.269
  21. Redaksi JSS. (2016). Pabrik Obat Murah. Retrieved from http://www.jurnalsocialsecurity.com/sosial/kesehatan/pabrik-obat-murah.html
  22. Redaksi WE. (2021). Tantangan dan Kebijakan Vaksin Merah Putih untuk Percepatan Penanganan Pandemi Covid-19. Retrieved from https://www.wartaekonomi.co.id/read324256/tantangan-dan-kebijakan-vaksin-merah-putih-untuk-percepatan-penanganan-pandemi-covid-19
  23. Rizni, F. (2016). ASPEK DAN PELAKSANAAN NATIONAL DRUG POLICY DI INDONESIA. DEFENDONESIA, 1(2), 49–52.
  24. Sari, I. P., & Sriwidodo, S. (2020). Perkembangan Teknologi Terkini dalam Mempercepat Produksi Vaksin COVID-19. Majalah Farmasetika. Retrieved from https://doi.org/10.24198/mfarmasetika.v5i5.28082
  25. Satgas Penanganan COVID-19. (2020). Analisis Data COVID-19 Indonesia Update Per 03 Januari 2021. Retrieved from https://covid19.go.id/
  26. Seto, S., Nita, Y., & Triana, L. (2015). Manajemen Farmasi 2: Edisi 4: Lingkup apotek, farmasi rumah sakit, industri farmasi, pedagang besar farmasi. Surabaya: Airlangga University Press.
  27. Usman, N. (2018). Implementasi Kebijakan Pengembangan Industri Alat Kesehatan Dalam Negeri. Jurnal Kebijakan Kesehatan Indonesia: JKKI, 7(1), 42–48. Retrieved from https://doi.org/10.22146/jkki.17936
  28. Zuhriyah, D. A. (2019). 2021, Impor Bahan Baku untuk Industri Farmasi Ditarget Turun 15%. Retrieved from https://ekonomi.bisnis.com/read/20191014/12/1158799/2021-impor-bahan-baku-untuk-industri-farmasi-ditarget-turun-15